首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1736681

2026 年至 2032 年電生理設備市場（按類型、適應症、最終用戶和地區分類）

Electrophysiology Devices Market By Type, Indication (Atrial Fibrillation, Supraventricular Tachycardia, Ventricular Tachycardia), End-User, Region for 2026-2032

出版日期: 2025年05月06日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

電生理設備市場評估-2026-2032

心血管疾病（尤其是心房顫動）的盛行率不斷上升，推動了對電生理設備的需求。因此，心血管疾病（尤其是心房顫動）的盛行率不斷上升將推動市場規模的成長，到2024年將達到86億美元，到2032年將達到193.1億美元。

老年人口的成長將導致心律不整的發病率上升，進而推動對電生理設備的需求。由於老年人口的成長，預計2026年至2032年期間市場複合年成長率將達到11.73%。

電生理設備市場定義/概述

電生理設備在心律不整和其他電生理異常的診斷和治療中發揮著至關重要的作用。這些先進的醫療設備旨在測量和分析心臟的電活動，為醫療保健專業人員，尤其是心臟病專家和電生理學家提供重要資訊。這些設備的主要功能是幫助識別異常心律，定位心臟內的心律不整部位，並提供治療性介入以恢復正常的心臟功能。

電生理學設備涵蓋各種工具，例如消融導管、診斷導管、標測系統和3D電解剖標測系統。診斷導管有助於測量心臟的電脈衝，而消融導管則用於將能量輸送到特定部位以治療異常心律。標測系統可即時可視化心臟的電活動，有助於精準診斷和針對性的治療。

電生理設備的進步徹底改變了心臟護理，使導管消融等微創手術成為可能。這些手術為患者提供了傳統開胸心臟外科手術的替代方案，顯著縮短了復健時間並改善了治療效果。隨著心臟病日益普遍，對電生理設備的需求預計將持續成長，使其成為現代心血管醫學不可或缺的工具。

心導管電氣燒灼術治療的普及是否會加速電生理設備市場的成長？

人們對微創治療的日益成長的偏好推動了心導管電氣燒灼術（電生理設備的主要應用）的採用。根據 2021 年發表在 JAMA Network Open 上的一項研究，2010 年至 2018 年間，美國用於治療心房顫動的心導管電氣燒灼術使用量增加了 51%。這歸因於醫療成本的上升和醫療基礎設施的改善。醫療保健支出的增加，尤其是在新興國家，正在推動先進電生理設備的採用。根據世界銀行的報告，全球醫療保健支出佔 GDP 的比例已從 2010 年的 9.7% 上升到 2019 年的 9.9%，顯示對醫療保健技術的投資正在不斷擴大。

醫院外的應用正在不斷擴展。可攜式和穿戴式式電生理設備在遠端患者監護中的應用日益廣泛，這正在創造新的市場機會。根據 Verified Market Research 的研究報告，包括心臟監測設備在內的遠端患者監護市場在 2023 年的價值為 417.7 億美元，預計到 2032 年將達到 1,583.9 億美元，2026 年至 2032 年的複合年成長率為 20%。此外，電生理技術的不斷創新正在擴展這些設備的功能和應用。美國食品藥物管理局 (FDA) 在 2021 年核准了132 種新的醫療設備，其中許多屬於心血管領域。

電生理學程序和設備的高成本將如何阻礙電生理學設備市場的成長？

電生理學程序和設備價格昂貴，這可能會限制市場成長，尤其是在新興國家。根據 2021 年發表在《心房顫動雜誌》上的一項研究，在美國，心房顫動心導管電氣燒灼術的平均費用在 18,000 美元到 32,000 美元之間，具體取決於所使用的技術和醫療環境。缺乏訓練有素的專業人員來執行複雜的電生理學程序，這正在抑制市場擴張。根據心律學會 2022 年的報告，美國祇有約 3,500 名心臟電生理學專家為超過 3.3 億人口提供服務。這意味著每 94,000 人中只有一名電生理學家，這表明存在嚴重的人才短缺。

電生理治療期間可能出現不利事件，這使得一些患者和醫療保健提供者不願意接受該治療。 2020 年發表在《歐洲心臟雜誌》上的一項大型研究發現，心導管電氣燒灼術治療的總體併發症發生率為 5.5%，其中 1.7% 的患者出現嚴重併發症。新型電生理設備的監管途徑漫長而複雜，減緩了市場成長。美國 FDA 在 2022 年年度績效報告中報告稱，醫療設備核准(PMA) 申請的平均決策時間為 365 天。這一延長的時間大大延遲了新型電生理技術的市場推廣。

The rising incidence of cardiovascular diseases, particularly atrial fibrillation, is driving the demand for electrophysiology devices. Thus, the increasing prevalence of cardiovascular diseases, especially atrial fibrillation surged the growth of market size surpassing USD 8.6 Billion in 2024 to reach the valuation of USD 19.31 Billion by 2032.

Increasing geriatric population increases the incidences of cardiac arrhythmias increases, boosting the demand for electrophysiology devices. Thus, the growing aging population enables the market to grow at a CAGR of 11.73% from 2026 to 2032.

Electrophysiology Devices Market: Definition/ Overview

Electrophysiology devices play a critical role in the diagnosis and treatment of cardiac arrhythmias and other electrical abnormalities of the heart. These sophisticated medical instruments are designed to measure and analyze the heart's electrical activity, providing vital information to healthcare professionals, particularly cardiologists and electrophysiologists. The primary function of these devices is to identify abnormal heart rhythms, pinpoint arrhythmogenic areas within the heart, and assist in delivering therapeutic interventions to restore proper cardiac function.

Electrophysiology devices encompass a wide range of tools, including ablation catheters, diagnostic catheters, mapping systems, and 3D electroanatomical mapping systems. Diagnostic catheters help in measuring electrical impulses in the heart, while ablation catheters are used to deliver energy to specific areas to treat abnormal heart rhythms. Mapping systems provide real-time visualization of the heart's electrical activity, aiding in accurate diagnosis and precise treatment.

The advancement of electrophysiology devices has revolutionized cardiac care, allowing for minimally invasive procedures like catheter-based ablations. These procedures offer patients an alternative to traditional open-heart surgery, significantly reducing recovery time and improving outcomes. As cardiac conditions become more prevalent, the demand for electrophysiology devices is expected to grow, making them indispensable tools in modern cardiovascular medicine.

How does the Increasing Adoption of Catheter Ablation Procedures Surge the Growth of the Electrophysiology Devices Market?

The growing preference for minimally invasive procedures is boosting the adoption of catheter ablation, a key application of electrophysiology devices. A study published in JAMA Network Open in 2021 found that the use of catheter ablation for atrial fibrillation increased by 51% between 2010 and 2018 in the United States. Rising healthcare expenditure and improving healthcare infrastructure. Increased healthcare spending, particularly in emerging economies, is facilitating the adoption of advanced electrophysiology devices. The World Bank reports that global healthcare expenditure as a percentage of GDP increased from 9.7% in 2010 to 9.9% in 2019, indicating a growing investment in healthcare technologies.

Expanding applications in out-of-hospital settings. The increasing use of portable and wearable electrophysiology devices for remote patient monitoring is opening new market opportunities. According to a report by Verified Market Research, the Remote Patient Monitoring Market, which includes cardiac monitoring devices, was valued at USD 41.77 Billion in 2023 and is expected to reach USD 158.39 Billion by 2032, with a growing CAGR of 20% from 2026 to 2032. In addition, the continuous innovations in electrophysiology technologies are expanding the capabilities and applications of these devices. The FDA approved 132 new medical devices in 2021, many of which were in the cardiovascular space.

How Does the High Cost of Electrophysiology Procedures and Devices Impede the Growth of the Electrophysiology Devices Market?

The expensive nature of electrophysiology procedures and devices can limit market growth, especially in developing countries. According to a study published in the Journal of Atrial Fibrillation in 2021, the average cost of catheter ablation for atrial fibrillation in the United States ranged from $18,000 to $32,000, depending on the technology used and the healthcare setting. The lack of trained professionals to perform complex electrophysiology procedures restrains market expansion. A 2022 report by the Heart Rhythm Society stated that there were only about 3,500 board-certified cardiac electrophysiologists in the United States, serving a population of over 330 million. This translates to approximately 1 electrophysiologist per 94,000 people, indicating a significant shortage.

The potential for adverse events during electrophysiology procedures can deter some patients and healthcare providers. A large-scale study published in the European Heart Journal in 2020 found that the overall complication rate for catheter ablation procedures was 5.5%, with 1.7% of patients experiencing major complications. Lengthy and complex regulatory pathways for new electrophysiology devices slow down market growth. The U.S. FDA reported in its 2022 annual performance report that the average time to decision for premarket approval (PMA) applications for medical devices was 365 days. This extended timeline significantly delays the introduction of new electrophysiology technologies to the market.

Category-Wise Acumens

How does the Increasing Heart Failure Incidence in the Growing Aging Population Surge the Growth of the Ablation Catheter Segment?

The ablation catheter segment holds a dominant position in the electrophysiology devices market, driven by its critical role in managing irregular heartbeats that are unresponsive to medication. Ablation catheters are utilized to perform procedures such as radiofrequency (RF) ablation, cryoablation, and pulse field ablation, each offering distinct methods to target and treat abnormal electrical pathways in the heart. The rising incidence of heart failure and arrhythmias, particularly in aging populations. As the elderly are more susceptible to cardiovascular diseases, the demand for effective and reliable electrophysiology treatments, such as ablation catheters, is expected to surge during the forecast period.

The growing awareness of the reliability and success rates of electrophysiology procedures, coupled with continuous advancements in electrophysiology (EP) technology, has significantly boosted the adoption of these devices. Minimally invasive procedures have become increasingly popular, as they offer shorter recovery times, fewer complications, and better patient outcomes compared to traditional open-heart surgeries. Ablation catheters are at the forefront of this shift, as they provide precise, safe, and effective treatment options for a wide range of arrhythmias.

How do the Rising Valvular Heart Disease and High Blood Pressure Cases Foster the Growth of the Atrial Fibrillation (AF) Segment?

The atrial fibrillation (AF) segment is emerging as a dominant in the electrophysiology devices market, driven by the rising incidence of risk factors such as valvular heart disease, high blood pressure, coronary artery disease, and cardiomyopathy, all closely linked to AF. With the global prevalence of AF steadily increasing, there is growing awareness of its severe complications, including stroke, which has heightened the demand for effective treatment options. One of the most impactful treatments is catheter ablation, and its widespread adoption is playing a pivotal role in driving the growth of this segment.

The integration of combination therapies, where electrophysiology devices are used alongside medications to manage various arrhythmias, is further shaping market trends. This multifaceted approach not only improves treatment outcomes but also boosts demand for advanced electrophysiology devices. Additionally, ongoing research into expanding the scope of ablation procedures for arrhythmias beyond AF is expected to create new growth opportunities. As more indications for electrophysiology procedures emerge, niche segments within the market are likely to experience increased investment and innovation. The prominence of AF treatments, particularly catheter ablation, and the continuous advancements in technology ensure that the AF segment will continue to dominate the electrophysiology devices market in the coming years.

How did the High Prevalence of Cardiovascular Diseases and Robust Healthcare Infrastructure Escalate the Growth of the Electrophysiology Devices Market in North America?

The increasing incidence of cardiovascular diseases, especially atrial fibrillation, is a major driver for the electrophysiology devices market in North America. According to the American Heart Association's 2022 Heart Disease and Stroke Statistics update, an estimated 12.1 million people in the United States are projected to have atrial fibrillation by 2030. This represents a significant increase from the 5.2 million cases reported in 2010, indicating a growing need for electrophysiology devices and procedures.

North America's advanced healthcare system and substantial healthcare spending contribute significantly to the growth of the electrophysiology devices market. The Centers for Medicare & Medicaid Services (CMS) reported that U.S. healthcare spending grew 2.7% in 2021 to reach USD 4.3 Trillion, or $12,914 per person. This high level of healthcare expenditure facilitates the adoption of advanced medical technologies, including electrophysiology devices.

The growing preference for minimally invasive electrophysiology procedures is driving market growth in North America. A study published in the Journal of the American College of Cardiology in 2021 reported that the use of catheter ablation for atrial fibrillation in the United States increased by 26% between 2016 and 2020. The study also found that minimally invasive ablation procedures were associated with shorter hospital stays and lower complication rates compared to traditional surgical approaches, further driving their adoption.

How does the High Prevalence of Cardiovascular Diseases and Increasing Life Expectancy Accelerate the Growth of the Electrophysiology Devices Market in Europe?

The increasing incidence of cardiovascular diseases, especially atrial fibrillation, is driving the demand for electrophysiology devices in Europe. According to the European Society of Cardiology's 2021 Cardiovascular Disease Statistics, over 11 million people in Europe were living with atrial fibrillation in 2020. The report projected this number to increase by 70% by 2030, reaching nearly 17 million cases. This significant growth in atrial fibrillation cases is expected to boost the demand for electrophysiology devices and procedures in the region.

Europe's aging population and rising life expectancy are contributing to the growth of the electrophysiology devices market. Eurostat reported in 2022 that the proportion of people aged 65 years and over in the EU is projected to increase from 20.8% in 2021 to 31.3% by 2100. This demographic shift is likely to increase the incidence of cardiac arrhythmias, driving the demand for electrophysiology devices and procedures.

The European market is seeing a growing adoption of advanced electrophysiology technologies and minimally invasive procedures. A study published in the European Heart Journal in 2023 reported that the number of catheter ablation procedures for atrial fibrillation in Europe increased by 15% between 2019 and 2022. The study also noted that centers performing these procedures grew from 498 to 579 during the same period, indicating a widespread adoption of advanced electrophysiology techniques across the continent.

Competitive Landscape

The Electrophysiology Devices Market is a highly competitive landscape, driven by factors such as technological advancements, increasing prevalence of heart diseases, and growing demand for minimally invasive procedures. Several key players operate in this market, offering a range of products and services to meet the diverse needs of healthcare providers and patients.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the electrophysiology devices market include:

Siemens AG
Medtronic Plc
Abbot Laboratories
GE Healthcare
Boston Scientific Corporation
Biosense Webster, Inc.
Nihon Kohden Corporation
Biotronik SE & CO. KG
Microport Scientific Corporation
Koninklijke Philips N.V.

Latest Developments:

In March 2021, Beaumont Health announced the launch of a new atrial fibrillation ablation technique to determine if pulsed field ablation may be used to treat individuals with irregular heartbeats.

1 INTRODUCTION OF GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
3.5 Market attractiveness

4 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY TYPE

5.1 Overview
5.2 Ablation Catheters
5.3 Diagnostic Catheters
5.4 Laboratory Devices
5.5 Mapping System
5.6 Accessories
5.7 Others

6 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY INDICATION

6.1 Overview
6.2 Atrial Fibrillation
6.3 Supraventricular Tachycardia (SVT)
6.4 Ventricular Tachycardia
6.5 Others

7 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY END-USE

7.1 Overview
7.2 Hospitals
7.3 Ambulatory Surgical Centers
7.4 Others

8 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL ELECTROPHYSIOLOGY DEVICES MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
9.4 ACE Matrix

10 COMPANY PROFILES

10.1 Siemens AG
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Medtronic Plc
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Abbot Laboratories
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 GE Healthcare
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Boston Scientific Corporation
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Biosense Webster, Inc.
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Nihon Kohden Corporation
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Biotronik SE & CO. KG
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Koninklijke Philips N.V.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Microport Scientific Corporation
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments